- Home
- KALU vs SVRA Comparison
KALU vs SVRA Comparison
Compare KALU & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALU | SVRA |
|---|---|---|
| Founded | 1946 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.1B |
| IPO Year | 2006 | 2009 |
Fundamental Metrics
Financial Performance| Metric | KALU | SVRA |
|---|---|---|
| Price | $127.38 | $5.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $107.00 | $7.33 |
| AVG Volume (30 Days) | 205.8K | ★ 1.3M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 135.89 | N/A |
| EPS | ★ 6.77 | N/A |
| Revenue | ★ $1,585,900,000.00 | N/A |
| Revenue This Year | $13.37 | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | $18.84 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $46.81 | $1.89 |
| 52 Week High | $150.00 | $7.01 |
Technical Indicators
Market Signals| Indicator | KALU | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 47.05 |
| Support Level | $116.89 | $5.47 |
| Resistance Level | $136.10 | $6.10 |
| Average True Range (ATR) | 5.65 | 0.28 |
| MACD | -1.13 | -0.02 |
| Stochastic Oscillator | 51.95 | 32.62 |
Price Performance
Historical ComparisonAbout KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.